AxoGen (AXGN)
(Delayed Data from NSDQ)
$6.50 USD
-0.05 (-0.76%)
Updated Apr 19, 2024 04:00 PM ET
After-Market: $6.51 +0.01 (0.15%) 6:32 PM ET
3-Hold of 5 3
C Value A Growth B Momentum A VGM
Price, Consensus and EPS Surprise
AXGN 6.50 -0.05(-0.76%)
Will AXGN be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for AXGN based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for AXGN
Zacks.com featured highlights Protagonist Therapeutics, AxoGen, Western Digital and Phunware
Ekso Bionics (EKSO) Reports Q4 Loss, Tops Revenue Estimates
AXGN: What are Zacks experts saying now?
Zacks Private Portfolio Services
4 Must-Buy Stocks for Remarkable Earnings Acceleration
AxoGen (AXGN) Is a Great Choice for 'Trend' Investors, Here's Why
AxoGen, Inc. (AXGN) Hit a 52 Week High, Can the Run Continue?
Other News for AXGN
Axogen, Inc. to Report First Quarter 2024 Financial Results and Host Conference Call on May 2, 2024
AXGN Crosses Below Key Moving Average Level
Director Gregory Freitag Sells 25,000 Shares of Axogen Inc (AXGN)
New Accounting & Financial Operations Risk for AxoGen – What’s the Latest?
AxoGen files $100M mixed securities shelf